Repros Therapeutics Inc. RPRX was a big mover last session with its shares surging over 45% on the day. The surge came amid news that the company’s treatment for secondary hypogonadism, which results in low testosterone and a reduced sperm count in men, will be reviewed by the FDA today (Nov 30). Reflecting positive investor sentiment about the outcome, this development led to far more shares changing hands yesterday than in a normal session. The move breaks the recent trend of the company as the stock is now trading above the volatile price range of $1.47 to $2.08 since Oct 29.
This biopharmaceutical company has seen one positive estimate revision over the past 30 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock, going forward, to see if the price action witnessed on Black Friday can turn into more strength down the road.
Repros currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.
Investors interested in the biomed/gene industry may also consider Heska Corp. HSKA which carries a Zacks Rank #1 (Strong Buy).
Is RPRX going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment